<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Miyakawa R</submitter><funding>Intelligent Cosmos Academic Foundation</funding><funding>Seiichi Imai Memorial Foundation</funding><funding>Japan Society for the Promotion of Science</funding><pagination>95</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC10182672</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>16(1)</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>Ovarian cancer has the worst outcome among gynecological malignancies; therefore, biomarkers that could contribute to the early diagnosis and/or prognosis prediction are urgently required. In the present study, we focused on the secreted protein spondin-1 (SPON1) and clarified the prognostic relevance in ovarian cancer.&lt;h4>Methods&lt;/h4>We developed a monoclonal antibody (mAb) that selectively recognizes SPON1. Using this specific mAb, we determined the expression of SPON1 protein in the normal ovary, serous tubal intraepithelial carcinoma (STIC), and ovarian cancer tissues, as well as in various normal adult tissues by immunohistochemistry, and verified its clinicopathological significance in ovarian cancer.&lt;h4>Results&lt;/h4>The normal ovarian tissue was barely positive for</pubmed_abstract><journal>Journal of ovarian research</journal><pubmed_title>SPON1 is an independent prognostic biomarker for ovarian cancer.</pubmed_title><pmcid>PMC10182672</pmcid><funding_grant_id>21K15386</funding_grant_id><pubmed_authors>Watanabe T</pubmed_authors><pubmed_authors>Chiba H</pubmed_authors><pubmed_authors>Fujimori K</pubmed_authors><pubmed_authors>Kobayashi M</pubmed_authors><pubmed_authors>Kojima M</pubmed_authors><pubmed_authors>Miyakawa R</pubmed_authors><pubmed_authors>Hashimoto Y</pubmed_authors><pubmed_authors>Soeda S</pubmed_authors><pubmed_authors>Endo Y</pubmed_authors><pubmed_authors>Kobayashi Y</pubmed_authors><pubmed_authors>Furukawa S</pubmed_authors><pubmed_authors>Sugimoto K</pubmed_authors><pubmed_authors>Honda T</pubmed_authors><pubmed_authors>Asano S</pubmed_authors></additional><is_claimable>false</is_claimable><name>SPON1 is an independent prognostic biomarker for ovarian cancer.</name><description>&lt;h4>Background&lt;/h4>Ovarian cancer has the worst outcome among gynecological malignancies; therefore, biomarkers that could contribute to the early diagnosis and/or prognosis prediction are urgently required. In the present study, we focused on the secreted protein spondin-1 (SPON1) and clarified the prognostic relevance in ovarian cancer.&lt;h4>Methods&lt;/h4>We developed a monoclonal antibody (mAb) that selectively recognizes SPON1. Using this specific mAb, we determined the expression of SPON1 protein in the normal ovary, serous tubal intraepithelial carcinoma (STIC), and ovarian cancer tissues, as well as in various normal adult tissues by immunohistochemistry, and verified its clinicopathological significance in ovarian cancer.&lt;h4>Results&lt;/h4>The normal ovarian tissue was barely positive for</description><dates><release>2023-01-01T00:00:00Z</release><publication>2023 May</publication><modification>2025-04-22T14:39:16.929Z</modification><creation>2025-04-06T01:07:45.913Z</creation></dates><accession>S-EPMC10182672</accession><cross_references><pubmed>37179355</pubmed><doi>10.1186/s13048-023-01180-8</doi></cross_references></HashMap>